AJANTA PHARMA LTD. - 532331 - Disclosure Under Regulation 30 Of LODR
Please find attached herewith letter which is self-explanatory.21-07-2023
21-07-2023
AJANTA PHARMA LTD. - 532331 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Pursuant to Regulation 44 of LODR, we submit herewith the following: a. Details of voting results on each resolution set out in the notice and b. Consolidated Scrutinizers'' report dated 18th July 2023.18-07-2023
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Meeting Updates
Please find enclosed herewith proceedings of Annual General Meeting held on 18th July 2023 through VC/OAVM.18-07-2023
AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Considering And Approving Quarterly Results
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2023 ,inter alia, to consider and approve unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2023.14-07-2023
Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang
Net Sales are expected to increase by 9.6 percent Y-o-Y (up 18.2 percent Q-o-Q) to Rs 1,042.3 crore, according to Nirmal Bang.12-07-2023
AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed certificate under Reg. 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2023.11-07-2023
Ajanta Pharma looks to expand ops in high-growth Asian, African geographies
As part of its growth plans, Ajanta Pharma is looking to enhance its presence across select geographies with high growth potential in Asia and Africa. In its Annual Report for 2022-23, the Mumbai-based drug maker stated that it intends to rely on its strengths to grow faster in countries where it has a presence with its range of branded generics. "As we achieve formidable positions in many markets, our strategy now entails enhancing focus on select countries from our geographical presence, which promises high growth potential," Ajanta Pharma informed its shareholders. These territories offer a large branded generics pharma market size, but the company's presence still remains small, it added. "We plan to ramp up our presence in these markets and add value to the patients' choices through our differentiated product portfolio," the drug firm said. The company's branded generics business accounted for 73 per cent of its revenues in FY 2023, with Indian, rest of Asia and Africa...02-07-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 30, 2023 for Ravi Agrawal, trustee Ravi Agrawal Trust30-06-2023
AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to provisions of SEBI (PIT) Regulations, 2015 as amended from time to time, trading window shall be closed from the close of business hour of Friday, 30th June 2023 till 48 hours after the declaration of financial results of the Company.30-06-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 29, 2023 for Aayush Agrawal, trustee Aayush Agrawal Trust30-06-2023